Trial Profile

A phase II study of lenalidomide and prednisolone as post-ASCT maintenance therapy for patients with Multiple Myeloma incorporating residual disease monitoring

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Prednisolone
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms LEOPARD
Sponsors Celgene Corporation

Most Recent Events

08 Dec 2020 Results assessing mass cytometry (CyTOF) based immune profiling in patients with newly diagnosed Multiple Myeloma patients presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
23 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com